132 related articles for article (PubMed ID: 36945574)
1. The degree of T cell stemness differentially impacts the potency of adoptive cancer immunotherapy in a Lef-1 and Tcf-1 dependent manner.
Rangel Rivera GO; Dwyer CJ; Knochelmann HM; Smith AS; Aksoy A; Cole AC; Wyatt MM; Thaxton JE; Lesinski GB; Paulos CM
bioRxiv; 2023 Mar; ():. PubMed ID: 36945574
[TBL] [Abstract][Full Text] [Related]
2. Progressively Enhancing Stemness of Adoptively Transferred T Cells with PI3Kδ Blockade Improves Metabolism and Antitumor Immunity.
Rangel Rivera GO; Dwyer CJ; Knochelmann HM; Smith AS; Aksoy BA; Cole AC; Wyatt MM; Kumaresan S; Thaxton JE; Lesinski GB; Paulos CM
Cancer Res; 2024 Jan; 84(1):69-83. PubMed ID: 37801615
[TBL] [Abstract][Full Text] [Related]
3.
Hu X; Majchrzak K; Liu X; Wyatt MM; Spooner CJ; Moisan J; Zou W; Carter LL; Paulos CM
Cancer Res; 2018 Jul; 78(14):3888-3898. PubMed ID: 29769201
[TBL] [Abstract][Full Text] [Related]
4. B cells imprint adoptively transferred CD8
Smith AS; Knochelmann HM; Wyatt MM; Rangel Rivera GO; Rivera-Reyes AM; Dwyer CJ; Ware MB; Cole AC; Neskey DM; Rubinstein MP; Liu B; Thaxton JE; Bartee E; Paulos CM
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017148
[TBL] [Abstract][Full Text] [Related]
5. Human CD26
Bailey SR; Nelson MH; Majchrzak K; Bowers JS; Wyatt MM; Smith AS; Neal LR; Shirai K; Carpenito C; June CH; Zilliox MJ; Paulos CM
Nat Commun; 2017 Dec; 8(1):1961. PubMed ID: 29213079
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of tumor-reactive CD4
Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
[TBL] [Abstract][Full Text] [Related]
7. Targeting
Le PT; Ha N; Tran NK; Newman AG; Esselen KM; Dalrymple JL; Schmelz EM; Bhandoola A; Xue HH; Singh PB; Thai TH
Front Immunol; 2021; 12():738958. PubMed ID: 34721405
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
9. TCF-1 maintains CD8
Wen S; Lu H; Wang D; Guo J; Dai W; Wang Z
J Leukoc Biol; 2021 Sep; 110(3):585-590. PubMed ID: 34047386
[TBL] [Abstract][Full Text] [Related]
10. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Marotte L; Simon S; Vignard V; Dupre E; Gantier M; Cruard J; Alberge JB; Hussong M; Deleine C; Heslan JM; Shaffer J; Beauvais T; Gaschet J; Scotet E; Fradin D; Jarry A; Nguyen T; Labarriere N
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 32001504
[TBL] [Abstract][Full Text] [Related]
11. Engaging stemness improves cancer immunotherapy.
Dianat-Moghadam H; Sharifi M; Salehi R; Keshavarz M; Shahgolzari M; Amoozgar Z
Cancer Lett; 2023 Feb; 554():216007. PubMed ID: 36396102
[TBL] [Abstract][Full Text] [Related]
12. Inosine induces stemness features in CAR-T cells and enhances potency.
Klysz DD; Fowler C; Malipatlolla M; Stuani L; Freitas KA; Chen Y; Meier S; Daniel B; Sandor K; Xu P; Huang J; Labanieh L; Keerthi V; Leruste A; Bashti M; Mata-Alcazar J; Gkitsas N; Guerrero JA; Fisher C; Patel S; Asano K; Patel S; Davis KL; Satpathy AT; Feldman SA; Sotillo E; Mackall CL
Cancer Cell; 2024 Feb; 42(2):266-282.e8. PubMed ID: 38278150
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
14. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3.
Lauder SN; Smart K; Kersemans V; Allen D; Scott J; Pires A; Milutinovic S; Somerville M; Smart S; Kinchesh P; Lopez-Guadamillas E; Hughes E; Jones E; Scurr M; Godkin A; Friedman LS; Vanhaesebroeck B; Gallimore A
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093155
[TBL] [Abstract][Full Text] [Related]
16. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
18. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
[TBL] [Abstract][Full Text] [Related]
19. Identification of CEACAM5 as a stemness-related inhibitory immune checkpoint in pancreatic cancer.
Shi H; Tsang Y; Yang Y
BMC Cancer; 2022 Dec; 22(1):1291. PubMed ID: 36494785
[TBL] [Abstract][Full Text] [Related]
20. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
